Ameriprise
ELVN icon

Ameriprise’s Enliven Therapeutics ELVN Stock Holding History

Ameriprise’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.29M Buy
160,577
+141,628
+747% +$3.92M ﹤0.01% 2285
2025
Q4 		$292K Sell
18,949
-104,387
-85% -$2.08M ﹤0.01% 3811
2025
Q3 		$2.52M Buy
123,336
+64,092
+108% +$1.29M ﹤0.01% 2890
2025
Q2 		$1.19M Buy
59,244
+35,582
+150% +$674K ﹤0.01% 3193
2025
Q1 		$466K Sell
23,662
-11,397
-33% -$245K ﹤0.01% 3516
2024
Q4 		$789K Buy
+35,059
New +$909K ﹤0.01% 3343

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise's ELVN Position: Q1 2026 in Review

Ameriprise increased its Enliven Therapeutics (ELVN) stake by 747% in Q1 2026, buying an estimated $3.92M and bringing the position to 160,577 shares worth $6.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2285.

Ameriprise first reported a position in ELVN in Q4 2024 and has held it in 6 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Ameriprise held 160,577 shares of Enliven Therapeutics worth $6.29M as of Q1 2026.
  • Ameriprise bought 141,628 Enliven Therapeutics shares in Q1 2026, an estimated $3.92M.
  • Enliven Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2285 holding.
  • Ameriprise first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.